Harbor Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Harbor Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$725K	Buy	1,163 +10	+0.9%	+$6.81K	0.05%	444
2026 Q1	$891K	Sell	1,153 -429	-27%	-$328K	0.07%	348
2025 Q4	$1.22M	Sell	1,582 -1	-0.1%	-$679	0.09%	287
2025 Q3	$890K	Buy	1,583 +46	+3%	+$26K	0.07%	347
2025 Q2	$807K	Sell	1,537 -10	-0.6%	-$5.58K	0.03%	468
2025 Q1	$981K	Buy	+1,547	New	+$1.06M	0.04%	436
2024 Q1	–	Sell	-1,805	Closed	-$1.59M	–	838
2023 Q4	$1.59M	Hold	1,805	–	–	0.3%	86
2023 Q3	$1.49M	Hold	1,805	–	–	0.32%	76
2023 Q2	$1.3M	Hold	1,805	–	–	0.26%	95
2023 Q1	$1.48M	Buy	+1,805	New	+$1.36M	0.43%	71

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Harbor Capital Advisors's REGN Position: Q2 2026 in Review

Harbor Capital Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.87% in Q2 2026, buying an estimated $6.81K and bringing the position to 1,163 shares worth $725K. The position accounts for 0.05% of the portfolio, ranked #444.

Harbor Capital Advisors first reported a position in REGN in Q1 2023 and has held it in 10 quarters since. The position peaked at $1.59M in Q4 2023. 864 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Harbor Capital Advisors held 1,163 shares of Regeneron Pharmaceuticals worth $725K as of Q2 2026.
Harbor Capital Advisors bought 10 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.81K.
Regeneron Pharmaceuticals made up 0.05% of Harbor Capital Advisors's portfolio in Q2 2026, its #444 holding.
Harbor Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
Harbor Capital Advisors's Regeneron Pharmaceuticals position peaked at $1.59M in Q4 2023.
864 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.